CE 2018

Myelodysplastic Syndrome and the Chronic Leukemias

MDS is the most common life-threatening neoplastic blood disorder at older ages and the majority of cases are diagnosed incidentally based on unexpected CBC findings. Mortality is improving steadily in some subsets of chronic leukemias, enabling us to make competitive offers. We will cover all salient aspects of these 2 subjects in this course.

 

Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

NAFLD is the most common liver-related disorder in the world. In addition it has substantial cardiometabolic implications. NASH represents a critical subset of NAFLD cases with chronic liver fibrosis potentially progressing to cirrhosis and liver cancer. This course will focus on the diagnosis and management of NAFLD and above all on RED FLAGS associated with excess mortality and morbidity.  

 

Posttraumatic Stress Disorder (PTSD)

PTSD has the most profound mortality and morbidity implications of all so-called anxiety disorders. In addition, the incidence of PTSD diagnosis is increasing worldwide in all socioeconomic groups. This course will delve into the critical issues bearing on insurability with a special emphasis on RED FLAGS consistent with WORST CASE risks. 

 

Hypertrophic Cardiomyopathy (HCM)

HCM is the most common form of cardiomyopathy. Some cases are associated with high mortality in under age 35 whereas others are diagnostic incidentally at older ages and are sometimes insurable at standard rates. We will review all aspects of this challenging condition emphasizing factors correlating with high risk in all ages while also pinpointing BEST CASE criteria. 

 

Critical Issues in Pharmacology Underwriting

Our old adage “tell me what he’s taking and I’ll tell you what he’s got” has never been as important as today given the mushrooming array of both new drugs and off-label uses. The bounty we get from Rx records mandates a strong grounding in critical aspects of pharmacology bearing on insurability. This course will empower underwriters to use Rx details to make more decisions without medical records and dodge pitfalls seldom addressed in manuals. 

 

Recreational and Medicinal Marijuana Use

This virtual “primer on pot” will dissect every insurability salient issue. We will meticulously distinguish between misperceptions and proven implications regarding modes of consumption, testing, effects on every organ system, mortality studies, driving after cannabis ingestion, legal marketing and marijuana’s medicinal uses.

 

Frailty: RED FLAGS and Critical Issues  

Physical frailty and its precursor dubbed “pre-frailty” constitute the insidious X factor in excess mortality at age 70 and older. As its title suggests, this course will cover everything that contributes to the onset and progression of frailty including physical findings, symptoms, health habits, functional screening tools, lab test results and treatment options.

 

Emerging Issues in Tobacco and Alcohol Underwriting  

New insights into tobacco and alcohol are reshaping our perspective on how to best underwriting their use/abuse. We will dissect these developments, moving forward from our September 2017 analysis of the findings in the Tobacco, Alcohol and Drug Use Survey. 

 

Family History, Parental Longevity and Genomic Testing

Which aspects of family history impact mortality and what are the implications for preferred status? Is exceptional parental longevity a legitimate preferred criterion and if so on what basis. What are the insurability implications of the latest developments in genomic testing? This course will answer these and other questions in the realm of familial and inherited mortality. 

 

Brain and Spinal Cord Tumors

The mortality and morbidity implications of Central nervous system tumors are changing with advances in early diagnosis and treatment. This course will cover what underwriters need to know about benign and malignant CNS neoplasms.

 

Critical Issues in Metabolic Syndrome (MS) and Related Disorders

The prevalence of metabolic syndrome is increasing and the relative significance of its components differs by age, gender and treatment impact. Many other disorders and test findings have key correlations with this syndrome that influence its mortality and morbidity impact. This course will cover all relevant aspects of metabolic syndrome from an insurability perspective.

 

Colon Polyps and Cancer 

Colorectal carcinoma is one of the 3 leading fatal malignancies in both genders. Pathological criteria defining colon polyps and their association with invasive cancer have changed radically. Recent developments affecting diagnosis and treatment have major insurability implications. We will cover these issues as well as all RED FLAGS underwriters must know.